Skip to main content
Erschienen in: Medical Oncology 4/2007

01.12.2007

Capecitabine plus oxaliplatin (xelox) in the treatment of chemotherapy-naive patients with metastatic colorectal cancer

verfasst von: Emel Yaman, Aytug Uner, Ozlem Er, Ugur Coskun, Suleyman Buyukberber, Mustafa Dikilitas, Mevlude Polat, Deniz Yamac, Ali Osman Kaya, Ramazan Yildiz, Banu Ozturk, Mustafa Benekli, for Anatolian Society of Medical Oncology (ASMO)

Erschienen in: Medical Oncology | Ausgabe 4/2007

Einloggen, um Zugang zu erhalten

Abstract

Background

Capecitabine and oxaliplatin are both synergistically active against metastatic colorectal cancer (MCRC). We evaluated our experience at two centers with capecitabine and oxaliplatin combination (XELOX) in previously untreated patients with MCRC.

Patients and methods

We reviewed medical records of 85 previously untreated patients with MCRC who received first-line XELOX regimen. Oxaliplatin was given at a dose of 130 mg/m2 on day 1 in combination with capecitabine 1500 mg/m2/day on days 1–14 every 3 weeks.

Results

Seventy six of 85 patients were evaluated for response and toxicity. Patients with a follow up of less than 6 months were excluded from the study. Objective response rate was 46% including 8 complete responses (10.5%) and 27 partial responses (35.5%). Additionally, 20 patients (26.3%) had disease stabilization at least 3 months after the treatment. The patients were followed for a median 12.5 months (range 2–32). Median time to disease progression (TTP) was 11 months (range 2–27 months). Median overall survival (OS) time has not yet been reached. One-year survival rate was 66%. Toxicity was modest with infrequent grade 3–4 adverse effects.

Conclusion

XELOX is an active regimen against MCRC in the first-line setting with favorable toxicity profile. Our results appear to be comparable, if not superior, to the results of other reports of first-line XELOX therapy in respect to objective response rates, survival data, and safety profile. Convenience with oral administration of every 3-week schedule makes XELOX regimen a compelling therapeutic option in the treatment of first-line MCRC.
Literatur
1.
Zurück zum Zitat Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43–66.PubMed Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43–66.PubMed
2.
Zurück zum Zitat De Gramont A, Figer A, Seymour M, et al. Leucovorin and Fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938–47.PubMed De Gramont A, Figer A, Seymour M, et al. Leucovorin and Fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938–47.PubMed
3.
Zurück zum Zitat Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet 2000;355:1041–7.PubMedCrossRef Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet 2000;355:1041–7.PubMedCrossRef
4.
Zurück zum Zitat Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study. J Clin Oncol 2001;19:2282–92.PubMed Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study. J Clin Oncol 2001;19:2282–92.PubMed
5.
Zurück zum Zitat Chang DZ, Abbruzzese JL. Capecitabine plus oxaliplatin vs infusional 5-fluorouracil plus oxaliplatin in the treatment of colorectal cancer. Pro: The CapeOx regimen is preferred over FOLFOX. Clin Adv Hematol Oncol 2005;3:400–4.PubMed Chang DZ, Abbruzzese JL. Capecitabine plus oxaliplatin vs infusional 5-fluorouracil plus oxaliplatin in the treatment of colorectal cancer. Pro: The CapeOx regimen is preferred over FOLFOX. Clin Adv Hematol Oncol 2005;3:400–4.PubMed
6.
Zurück zum Zitat Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;3:205–16.CrossRef Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;3:205–16.CrossRef
8.
Zurück zum Zitat Kaplan EL, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc 1958;53:457–81.CrossRef Kaplan EL, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc 1958;53:457–81.CrossRef
9.
Zurück zum Zitat Cassidy J, Tabernero J, Twelves C, et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for metastatic with colorectal cancer. J Clin Oncol 2004;22:2084–91.PubMedCrossRef Cassidy J, Tabernero J, Twelves C, et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for metastatic with colorectal cancer. J Clin Oncol 2004;22:2084–91.PubMedCrossRef
10.
Zurück zum Zitat Shields AF, Zalupski MM, Marshall JL, Meropol NJ. Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine: a phase II trial. Cancer 2004;100:531–7.PubMedCrossRef Shields AF, Zalupski MM, Marshall JL, Meropol NJ. Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine: a phase II trial. Cancer 2004;100:531–7.PubMedCrossRef
11.
Zurück zum Zitat Hochster HS, Hart LL, Ramanathan RK, Hainsworth JD, Hedrick EE, Childs BH. Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): final analysis of the TREE-Study. J Clin Oncol 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006:3510. Hochster HS, Hart LL, Ramanathan RK, Hainsworth JD, Hedrick EE, Childs BH. Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): final analysis of the TREE-Study. J Clin Oncol 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006:3510.
12.
Zurück zum Zitat Martoni AA, Pinto C, Di Fabio F, et al. Capecitabine plus oxaliplatin (XELOX) versus protracted fluorouracil venous infusion plus oxaliplatin (pvifox) as first-line treatment in advanced colorectal cancer: a GOAM phase II randomized study (FOCA trial). Eur J Cancer 2006;42:3161–8.PubMedCrossRef Martoni AA, Pinto C, Di Fabio F, et al. Capecitabine plus oxaliplatin (XELOX) versus protracted fluorouracil venous infusion plus oxaliplatin (pvifox) as first-line treatment in advanced colorectal cancer: a GOAM phase II randomized study (FOCA trial). Eur J Cancer 2006;42:3161–8.PubMedCrossRef
13.
Zurück zum Zitat Zeuli M, Nardoni C, Pino MS, et al. Phase II study of capecitabine and oxaliplatin as first line treatment in advanced colorectal cancer. Ann Oncol 2003,14:1378–82.PubMedCrossRef Zeuli M, Nardoni C, Pino MS, et al. Phase II study of capecitabine and oxaliplatin as first line treatment in advanced colorectal cancer. Ann Oncol 2003,14:1378–82.PubMedCrossRef
14.
Zurück zum Zitat Makatsoris T, Kalofonos HP, Aravantinos G, et al. A phase II study of capecitabine plus oxaliplatin (XELOX): a new first line option in metastatic colorectal cancer. Int J Gastrointest Cancer 2005;35:103–9.PubMedCrossRef Makatsoris T, Kalofonos HP, Aravantinos G, et al. A phase II study of capecitabine plus oxaliplatin (XELOX): a new first line option in metastatic colorectal cancer. Int J Gastrointest Cancer 2005;35:103–9.PubMedCrossRef
15.
Zurück zum Zitat Cassidy J, Clarke S, Diaz-Rubio E, et al. XELOX vs. FOLFOX4: efficacy results from XELOX-1/NO16966, a randomized phase III trial in first-line metastatic colorectal cancer (MCRC). ASCO Gastrointestinal Cancers Symposium, January 19–21, 2007, Orlando FL: 270. Cassidy J, Clarke S, Diaz-Rubio E, et al. XELOX vs. FOLFOX4: efficacy results from XELOX-1/NO16966, a randomized phase III trial in first-line metastatic colorectal cancer (MCRC). ASCO Gastrointestinal Cancers Symposium, January 19–21, 2007, Orlando FL: 270.
16.
Zurück zum Zitat Feliu J, Salud A, Escudero P, et al. XELOX (capecitabine plus oxaliplatin) as first line treatment for elderly patients over 70 years of age with advanced colorectal cancer. Br J Cancer 2006;94:969–75.PubMedCrossRef Feliu J, Salud A, Escudero P, et al. XELOX (capecitabine plus oxaliplatin) as first line treatment for elderly patients over 70 years of age with advanced colorectal cancer. Br J Cancer 2006;94:969–75.PubMedCrossRef
17.
Zurück zum Zitat Comella P, Natale D, Farris A, et al. Capecitabine plus oxaliplatin for the first line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108. Cancer 2005;104:282–9.PubMedCrossRef Comella P, Natale D, Farris A, et al. Capecitabine plus oxaliplatin for the first line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108. Cancer 2005;104:282–9.PubMedCrossRef
18.
Zurück zum Zitat Twelves CJ, Butts Ca, Cassidy J, et al. Capecitabine/oxaliplatin, a safe and active first line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large phase II study. Clin Colorectal Cancer 2005;5:101–7.PubMedCrossRef Twelves CJ, Butts Ca, Cassidy J, et al. Capecitabine/oxaliplatin, a safe and active first line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large phase II study. Clin Colorectal Cancer 2005;5:101–7.PubMedCrossRef
Metadaten
Titel
Capecitabine plus oxaliplatin (xelox) in the treatment of chemotherapy-naive patients with metastatic colorectal cancer
verfasst von
Emel Yaman
Aytug Uner
Ozlem Er
Ugur Coskun
Suleyman Buyukberber
Mustafa Dikilitas
Mevlude Polat
Deniz Yamac
Ali Osman Kaya
Ramazan Yildiz
Banu Ozturk
Mustafa Benekli
for Anatolian Society of Medical Oncology (ASMO)
Publikationsdatum
01.12.2007
Verlag
Humana Press Inc
Erschienen in
Medical Oncology / Ausgabe 4/2007
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-007-0035-7

Weitere Artikel der Ausgabe 4/2007

Medical Oncology 4/2007 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.